Cardiovascular and metabolic trajectories in men engaged in a multidimensional preventive care program: a prospective observational study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Objectives

To describe within-individual changes in cardiometabolic, functional and neuroendocrine markers between two standardized evaluations in men engaged in a structured preventive care program, and to examine transitions across clinical risk categories.

Design

Prospective observational cohort study using routinely collected data; paired within-individual analyses.

Setting

Single preventive health center in Paris, France, offering a standardized multidisciplinary assessment with individualized lifestyle, supplementation and, when indicated, pharmacological recommendations.

Participants

279 men aged 18 years or older with a first evaluation (CU1) between October 2022 and November 2025 and a second evaluation (CU2) by May 2026 (32.3% of 865 eligible men); median interval 13.3 months (IQR 12.0–15.6). No exclusion criteria were applied.

Primary and secondary outcome measures

Within-individual change in continuous markers (Hodges– Lehmann estimate, 95% CI; Benjamini–Hochberg adjustment over 36 tests) and transitions across fixed clinical thresholds (paired odds ratios).

Results

Median age was 51.2 years, BMI 24.5 kg/m² and SCORE2 2.9%. Visceral adipose tissue mass decreased (Δ −49 g, 95% CI −80.5 to −18.5; q=0.006), with small decreases in body mass and fat mass. Handgrip strength increased (right +2.35 kg, 1.70 to 3.00; left +1.70 kg, 1.05 to 2.30; q<0.001). HDL cholesterol increased (+3.5 mg/dL, 2.5 to 4.5; q<0.001), with decreases in the triglyceride/HDL and total/HDL ratios. Blood pressure, LDL cholesterol, fasting glucose (after adjustment), insulin, HOMA-IR, SCORE2 and salivary cortisol and DHEA did not change. The proportion of men below the grip strength reference value decreased from 60.1% to 47.6% (paired OR 0.34, 0.19 to 0.61) and with HDL cholesterol ≤46 mg/dL from 26.7% to 16.5% (OR 0.25, 0.12 to 0.54).

Conclusions

IIn this selected, health-engaged population of men who completed both evaluations, changes in a favorable direction were observed for handgrip strength, HDL cholesterol and visceral adiposity, whereas blood pressure, LDL cholesterol, glycemic markers and SCORE2 were stable. Without a comparison group, these changes cannot be distinguished from regression to the mean, test–retest effects or secular trends.

Strengths and limitations of this study

  • Standardized assessment protocol applied identically at both evaluations, combining clinical, laboratory, DEXA body composition, functional and salivary neuroendocrine measurements in the same individuals.

  • Paired within-individual analyses of 36 markers in 279 men, reported as effect estimates with confidence intervals and a global false discovery rate adjustment, with sensitivity analyses by follow-up interval and calendar period and a comparison of returners with 586 eligible non-returners.

  • Single-arm design without a comparison group: the observed changes cannot be distinguished from regression to the mean, test–retest effects, participation effects or secular trends.

  • Highly selected population of urban, socioeconomically advantaged, health-engaged men, of whom 32% returned for a second evaluation, limiting generalizability to the general population and to high-risk groups.

  • Standardized effect sizes were small for most markers, adherence to recommendations was not measured objectively, and the follow-up was short.

Article activity feed